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ABSTRACT
Hypertension is one of the risk factors for cardiovascular diseases and has been associated with about 13% of global deaths 
worldwide. Oxidative stress and reduced nitric oxide (NO) bioavailability contribute to the development of endothelial 
dysfunction and subsequently hypertension. Nɷ-nitro-L-arginine methyl ester hydrochloride (L-NAME) inhibits NO synthesis; 
leading to hypertension. Piper sarmentosum (PS) is an herb with antioxidant, antiatherosclerosis and antiinflammation 
properties. PS also stimulated NO production by endothelial cells. The aim of this study was to determine the effects of 
aqueous extract of Piper sarmentosum (AEPS) on blood pressure, oxidative stress and the level of nitric oxide in L-NAME-
induced hypertensive rats. Hypertension was induced by oral administration of L-NAME (100 mg/L) in drinking water for 
four weeks. The rats were concurrently treated with AEPS by oral gavage in serial doses (125, 250 and 500 mg/kg/day). 
Blood pressure was measured using non-invasive tail-cuff method at baseline and fortnightly thereafter. Serum level of 
NO and an oxidative stress marker, malondialdehyde (MDA) were measured at baseline and at the end of treatment. The 
results showed that treatment with three different doses of AEPS successfully reduced systolic blood pressure (p<0.001), 
diastolic blood pressure (p<0.05) and mean arterial pressure (p<0.05) in L-NAME-induced hypertensive rats. Treatment 
with AEPS also reduced MDA level (p<0.001) and increased serum NO (p<0.001) in L-NAME-induced hypertensive rats. 
The findings showed that AEPS decreased blood pressure by protecting against oxidative stress and increasing NO in 
L-NAME-induced hypertensive rats. 
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ABSTRAK
Hipertensi merupakan salah satu faktor risiko penyakit kardiovaskular dan ia dikaitkan dengan kira-kira 13% kematian 
di seluruh dunia. Stres oksidatif dan pengurangan ketersediaan biologi nitrik oksida (NO) menyumbang kepada 
terjadinya disfungsi endotelium yang seterusnya menyebabkan hipertensi. Nɷ-nitro-L-arginina metil ester hidroklorida 
(L-NAME) merencat sintesis NO dan menyebabkan hipertensi. Piper sarmentosum (PS) adalah herba yang mempunyai 
sifat antioksidan, antiaterosklerosis dan antiinflamasi. PS juga merangsang pengeluaran NO oleh sel endotelium. Tujuan 
kajian ini adalah untuk menentukan kesan ekstrak akueus Piper sarmentosum (AEPS) terhadap tekanan darah, stres 
oksidatif dan aras nitrik oksida dalam tikus hipertensi aruhan L-NAME. Hipertensi diaruh dengan pemberian L-NAME 
(100 mg/L) secara oral di dalam air minuman selama empat minggu. Dalam masa yang sama, rawatan tikus dengan 
AEPS turut diberi serentak melalui gavaj oral dalam dos bersiri (125, 250 dan 500 mg/kg/hari). Tekanan darah diukur 
menggunakan kaedah kuf ekor tidak invasif sebelum rawatan dimulakan dan setiap dua minggu selepas itu. Aras serum 
NO dan penanda stres oksidatif, malondialdehida (MDA) diukur sebelum uji kaji dimulakan dan selepas rawatan tamat. 
Keputusan menunjukkan rawatan dengan tiga dos AEPS yang berbeza berjaya menurunkan tekanan darah sistolik (p< 
0.001), tekanan darah diastolik (p<0.05) dan tekanan arteri purata (p<0.05) dalam tikus hipertensi aruhan L-NAME. AEPS 
juga menurunkan aras MDA (p<0.01) dan meningkatkan aras NO (p<0.001) dalam serum tikus hipertensi aruhan L-NAME. 
Keputusan yang diperoleh menunjukkan bahawa AEPS berupaya menurunkan tekanan darah dengan mengurangkan stres 
oksidatif dan meningkatkan aras NO pada tikus hipertensi aruhan L-NAME.
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INTRODUCTION
Hypertension is defined as persistent elevation of systolic 
blood pressure of 140 mmHg or greater and/or diastolic 
BP of 90 mmHg or greater. According to World Health 
Statistic, it was reported that non-communicable diseases 
(NCD) were mostly caused by cardiovascular diseases 
(CVD) which accounted for 31% of global deaths (Mendis 
2014). Hypertension is one of the risk factors for CVD and 
has been associated with about 17 million deaths annually. 
It contributes to kidney failure, stroke, heart disease and 
premature mortality. In the early stage, hypertension is 
asymptomatic and many people go undiagnosed (WHO 2012).
2422 
 Endothelial dysfunction (ED) has been observed in 
the early stage of hypertension and it is the commonest 
contributing factor to hypertension (Park & Park 2015). 
Several studies had suggested that oxidative stress 
contributed to the development of hypertension through 
nitric oxide (NO) inactivation (Baradaran et al. 2014; Sinha 
& Kumar Dabla 2015). Increased free radical production as 
well as imbalance between the level of NO and endothelial 
vasoconstrictors such as endoperoxides, endothelins 
and thromboxane A lead to endothelial dysfunction and 
hypertension (Davidge et al. 2015; Panth et al. 2016; 
Vanhoutte et al. 2017). 
 Many methods to induce hypertension had been 
used in animal models. Nω-nitro-L-arginine methyl ester 
hydrochloride (L-NAME), an L-arginine analogue, acts 
as a competitive inhibitor of non-specific nitric oxide 
synthases (NOS). L-NAME has been widely used to create 
NO-deficient hypertensive model. It is well established 
that inhibition of nitric oxide biosynthesis by in vivo 
administration of L-NAME causes endothelial dysfunction 
and vasoconstriction, hence leading to hypertension (Raja 
2010).
 Piper sarmentosum is a herb that had been reported 
to have antioxidant activity (Hafizah et al. 2010). Toxicity 
studies on aqueous extract of PS showed that the extract is 
safe for consumption (Mohd Zainudin et al. 2013). Previous 
studies had reported various medicinal effects of PS such as 
antihyperglycemia (Azlina et al. 2009), antiatherosclerosis 
(Amran et al. 2010), anticarcinogenesis (Ariffin et al. 2009) 
and antiinflammation (Ridtitid et al. 2007; Zakaria et al. 
2010). Apart from that, PS is also able to protect against 
glucocorticoid-induced osteoporosis (Mohamad Asri et 
al. 2016) and paracetamol-induced oxidative liver injury 
(Azlina et al. 2014). Previous studies had shown that PS is 
able to reduce blood pressure in spontaneously hypertensive 
rats (SHR) (Zainudin et al. 2015). Aqueous extract of PS is 
able to stimulate NO production in human umbilical vein 
endothelial cells (HUVECs) (Ugusman et al. 2012). This 
suggests that PS may regulate blood pressure via the NO 
pathway. Therefore, this study was designed to determine 
the effects of PS on blood pressure, oxidative stress and 
NO level in L-NAME-induced hypertensive Wistar rats.
MATERIALS AND METHODS
PLANT MATERIALS
Fresh leaves of PS were collected in Selayang, Selangor, 
Malaysia between January to February 2012 and were 
identified by a plant taxonomist from the Medicinal Plant 
Division, Forest Research Institute of Malaysia with plant 
identification number (PID) 170612-11. 
PREPARATION OF AQUEOUS EXTRACT                                          
OF PIPER SARMENTOSUM 
Aqueous extract of Piper sarmentosum was prepared 
following the method as reported previously (Mohd 
Zainudin et al. 2013). Briefly, the leaves of PS were oven-
dried for 36 h at 50°C. Then the dried leaves were cut into 
small pieces and crushed. 10 g of dried leaves were mixed 
with 900 mL of distilled water. Hot water extraction was 
prepared by boiling the mixture at 80°C for 3 h. Then, the 
extract was concentrated and freeze-dried into powder 
form. It was stored at 4°C until use.
EXPERIMENTAL ANIMALS
This study had been approved by the Animal Ethics 
Committee, Universiti Kebangsaan Malaysia (approval 
code: PP/FISIO/2011/AMINUDDIN/22-MARCH/360-JUNE-
2011-JUNE-2012). Healthy adult male Wistar rats, aged 6 
to 8 weeks, weighing between 170-220 g were obtained 
from the Laboratory Animal Resource Unit, Universiti 
Kebangsaan Malaysia. The rats were maintained in an 
air-conditioned room at 23 ± 3°C and were housed in 
individual cages with a 12-h light and 12-h dark cycle. 
The rats were provided with normal rat chow and clean 
drinking water ad libitum. The rats were acclimatized for 
one week before the experiment started. 
EXPERIMENTAL DESIGN AND INDUCTION                                   
OF HYPERTENSION
Thirty six animals were divided into six groups with six 
animals in each group (n=6): control group; Aqueous 
extract Piper sarmentosum (AEPS) only group where the 
rats were given 500 mg/kg/day AEPS via oral gavage; 
L-NAME-induced hypertensive group was given 100 mg/L 
L-NAME in drinking water and three groups of L-NAME-
induced-hypertensive rats with co-treatment of different 
doses of AEPS; 100 mg/L L-NAME and 125 mg/kg/day AEPS; 
100 mg/L L-NAME and 250 mg/kg/day AEPS; and 100 mg/L 
L-NAME and 500 mg/kg/day AEPS. The treatments were 
given for four weeks (Wheal et al. 2007). Group 2 was 
included in this study to investigate whether AEPS on its 
own could affect the parameters measured in this study. All 
the three doses of AEPS were adopted from previous study 
on anti-atherosclerosis effect of AEPS (Amran et al. 2010).
DETERMINATION OF BLOOD PRESSURE
Systolic blood pressure (SBP), diastolic blood pressure 
(DBP) and mean arterial pressure (MAP) were measured 
in non-anaesthetized rats by non-invasive tail-cuff CODA 
blood pressure system (Kent Scientific Corporation, USA) 
at baseline and every two weeks after starting treatment 
(Zainudin et al. 2015). At least five readings were recorded 
during each measurement. The maximum and minimum 
values were discarded and the remaining three values were 
calculated as the average (Si & Liu 2008; Yang et al. 2008).
BLOOD SAMPLES COLLECTION
Blood samples (2 mL) were obtained in the morning 
at baseline and at the end of four weeks treatment via 
retro orbital sinus puncture with the animal under the 
  2423
combination anaesthesia of Zoletil, Xylazil and Ketamine 
and were collected in plain tubes. The blood samples were 
centrifuged at 3000 rpm for 10 min to obtain the serum. 
After the separation, the serum was aspirated and was 
frozen at -80°C until further experiments. 
DETERMINATION OF NITRIC OXIDE LEVEL
Since nitric oxide is unstable in aqueous condition and 
has a short half-life, the level of its stable metabolites, 
nitrite (NO2-) and nitrate (NO3-) was measured based on Griess method using QuantiChromTM nitric oxide assay kit 
(BioAssay Systems, USA) according to the manufacturer’s 
instructions. Total NO2-/NO3- in the serum samples were 
quantitated by measuring the optical density at 540 nm.
DETERMINATION OF PLASMA 
MALONDIALDEHYDE (MDA)
The lipid peroxidation indicator, plasma MDA was 
measured using thiobarbituric acid reactive substances 
(TBARS) assay as described previously (Borges et al. 
2018). Total protein concentration in the serum was 
measured using protein biuret reaction (Pessoa et al. 
2017). Plasma MDA level was calculated based on the 
following formula:
 OD sample × standard × Total volume
       OD standard   concentration  volume sample × protein (g)
Plasma level of MDA was expressed as nmol/g protein
STATISTICAL ANALYSIS
All statistical analysis was conducted using IBM SPSS 
Statistic version 22.0. The data were expressed as mean ± 
SEM. SBP, DBP and MAP results were analysed using one-
way analysis of variance (ANOVA) with Tukey post-hoc 
test while serum nitric oxide and malondialdehyde level 
were analysed using paired t-test. P< 0.05 was considered 
statistically significant.
RESULTS
EFFECT OF AEPS ON SYSTOLIC BLOOD PRESSURE
At baseline, there was no significant difference in SBP 
among the groups. Following two weeks of treatment, 
L-NAME-induced rats had higher SBP (155.3 ± 2.14 mmHg) 
compared to control rats (121.8 ± 0.60 mmHg) (p< 0.001). 
Treatment of L-NAME-induced rats with all three doses of 
AEPS (125, 250 and 500 mg/kg/day) successfully reduced 
SBP to normal level (128.0 ± 4.37, 127.8 ± 5.19 and 
122.17 ± 4.48 mmHg, respectively) (p< 0.001). At the 
end of four weeks treatment, the SBP of L-NAME-induced 
rats were persistently high compared to control (172.3 ± 
5.06 vs. 116.7 ± 1.52 mmHg, p< 0.001). Treatment with 
all three doses of AEPS significantly attenuated L-NAME-
induced rise in SBP at the end of treatment (126.0 ± 5.2, 
127.83 ± 3.79 and 129.67 ± 3.74 mmHg, respectively) 
(p< 0.001). However, there was no significant difference 
in SBP between the three doses of AEPS following two and 
four weeks of treatment. In addition, administration of 
AEPS alone did not significantly alter the SBP compared 
to control.
EFFECT OF AEPS ON DIASTOLIC BLOOD PRESSURE
At baseline, there was no significant difference in DBP 
among the groups. Following two weeks of treatment, 
L-NAME-induced rats had higher DBP (112.2 ± 3.25 mmHg) 
compared to control rats (83.6 ± 1.23 mmHg) (p< 0.01). 
Treatment of L-NAME-induced rats with three doses of 
AEPS (125, 250 and 500 mg/kg/day) successfully reduced 
DBP (94.0 ± 5.41, 87.0 ± 4.97 and 86.3 ± 8.2 mmHg) (p< 
0.05). At the end of the four weeks treatment, the DBP of 
L-NAME-induced rats were persistently high compared to 
control (127.5 ± 3.93 vs. 78.8 ± 2.41 mmHg, p<0.01). 
Treatment of L-NAME-induced rats with all three doses 
of AEPS significantly reduced DBP to normal level at the 
end of treatment (84.5 ± 4.38, 90.0 ± 2.44, and 86.3 ± 
4.19 mmHg, respectively) (p<0.05). However, there was 
*p<0.001 versus L-NAME group within the same week, # p<0.001 versus pre-treatment group 
FIGURE 1. Effect of AEPS on systolic blood pressure (SBP) in L-NAME induced hypertensive rats
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no significant difference in DBP between the three doses 
of AEPS following two and four weeks of treatment. In 
addition, administration of AEPS alone did not significantly 
alter the DBP compared to control.
EFFECT OF AEPS ON MEAN ARTERIAL BLOOD PRESSURE
The changes in MAP were in accordance to changes in SBP 
and DBP. At baseline, there was no significant difference in 
MAP among the groups. Following two weeks of treatment, 
L-NAME-induced rats had higher MAP (126.0 ± 2.45 mmHg) 
as compared to control rats (96.7 ± 0.88 mmHg) (p<0.05). 
Treatment of L-NAME-induced rats with all three doses of 
AEPS successfully reduced MAP (104.7 ± 4.97, 98.8 ± 3.93 
and 97.8 ± 6.89 mmHg) (p<0.05). At the end of the four 
weeks treatment, the MAP of L-NAME-induced rats were 
persistently high compared to control (142.0 ± 4.49 vs. 91.2 
± 1.78 mmHg, p< 0.05). Treatment of L-NAME-induced rats 
with all three doses of AEPS significantly reduced MAP at 
the end of treatment (97.0 ± 3.44, 101.2 ± 1.86 and 100.5 
± 2.71 mmHg, respectively) (p<0.05). However, there was 
no significant difference in MAP between the three doses 
of AEPS following two and four weeks of treatment. In 
addition, administration of AEPS alone did not significantly 
alter the MAP compared to control.
EFFECTS OF AEPS ON SERUM NO 
L-NAME induction caused reduction of serum NO compared 
to its pre-induction level (4.5 ± 1.92 vs 40.7 ± 6.26 
μM, p<0.05) as well as compared to control (p<0.001). 
Treatment with all three doses of AEPS (125, 250, 500 mg/
kg/day) increased serum NO compared to L-NAME group 
(p<0.001) with the values of 56.33 ± 9.15, 80.88 ± 8.55 
and 75.02 ± 8.46 μM, respectively. Apart from that, there 
was significant difference in the level of NO before and 
after treatment in AEPS, L-NAME + AEPS 250 mg/kg/day and 
L-NAME + AEPS 500 mg/kg/day groups (p<0.05).
*p<0.05 versus L-NAME within the same week, # p<0.01 versus pre-treatment group
FIGURE 2. Effect of AEPS on diastolic blood pressure (DBP) in L-NAME induced hypertensive rats
*p<0.05 vs L-NAME within the same week, # p<0.05 vs pre-treatment group 
FIGURE 3. Effect of AEPS on mean arterial pressure (MAP) in L-NAME induced hypertensive rats
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EFFECT OF AEPS ON SERUM MDA
Four weeks following L-NAME induction, serum MDA was 
increased compared to its pre-induction level (65.59 ± 
5.46 vs. 23.81 ± 4.33 nmol/g protein, p<0.01) as well as 
compared to control (p<0.05). Treatment with all three 
doses of AEPS (125, 250, 500 mg/kg/day) reduced serum 
MDA level compared to L-NAME group (p<0.05) with the 
values of 22.70 ± 3.63, 16.57 ± 4.64 and 25.15 ± 11.39 
nmol/g protein, respectively.
DISCUSSION
Hypertension is categorized into primary or essential 
hypertension (EH) and secondary hypertension. More than 
90% of hypertensive patients have EH whereby the cause 
is still unclear. Current studies suggest that NO deficiency 
contributes to EH (Arora et al. 2009). Increased in free 
radical generation inactivates prostacyclin and NO, hence 
causing half-life of prostacyclin and NO to be decreased. 
This situation may lead to increase in peripheral vascular 
resistance and subsequently hypertension (Kumar & 
Das 1993). Basal production of NO was reduced in 
spontaneously hypertensive rats (SHR) (Dohi et al. 1990). 
The endothelium-dependant vasodilator responses 
were attenuated in patients who suffered from essential 
hypertension which was mainly contributed to reduced 
bioactivity of NO (Panza et al. 1990). 
 The main objective in this study was to evaluate whether 
the high blood pressure in NO-deficient hypertensive 
rats induced by L-NAME, an L-arginine analogue that 
inhibits nitric oxide synthases could be improved by 
AEPS treatment. In the present study, the administration 
*p<0.001 versus L-NAME, # p<0.05 versus pre-treatment
FIGURE 4. Effect of AEPS on serum NO in L-NAME- induced-hypertensive rats 
*p<0.001 vs L-NAME; # p<0.05 vs L-NAME; + p<0.01 vs pre-treatment
FIGURE 5. Effect of AEPS on serum MDA level in L-NAME induced-hypertensive rats 
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of L-NAME in drinking water had induced hypertension 
in rats which concurred with previous studies (Raja 
2010). Concomitant treatment with serial doses of AEPS 
in the L-NAME-induced hypertensive rats had significantly 
attenuated the hypertension. 
 Nitric oxide produced by endothelial nitric oxide 
synthase (eNOS) is the major source of circulating 
NO. L-NAME interferes with the activity of eNOS, thus 
reducing NO production (Raja 2010). Since NO is a 
potent vasodilator, decreased NO production may impair 
endothelial-dependent vasodilation, causing increased 
peripheral resistance and blood pressure (Park & Park 
2015). Previous study had proven that PS increased NO level 
by stimulating eNOS expression and activity in HUVECs 
(Ugusman et al. 2010). Therefore, increased level of NO 
in L-NAME-induced hypertensive rats treated with AEPS 
could be due to increase in the activity of eNOS. A study 
by Ugusman et al. (2014) had found that a flavonoid, 
rutin, one of the compound in Piper sarmentosum, may 
improve endothelial function by augmenting NO production 
in HUVEC. Another recent study on PS showed that the 
extract was able to reduce blood pressure by increasing 
NO production in SHR (Zainudin et al. 2015). 
 Apart from inhibiting NO synthesis, L-NAME induces 
hypertension by causing oxidative stress. L-NAME is 
responsible to cause imbalance in renin-angiotensin 
system (RAS) whereby it increased the expression of 
angiotensin II and also caused renal dysfunction (Rincon 
et al. 2015). The excessive production of angiotensin 
II leads to increase vascular superoxide (O2-) formation 
through increased expression of NADPH-dependent oxidase 
in aortic smooth muscle cells (Tsai et al. 2016). The 
excessive O2- react rapidly with NO to form peroxynitrite 
(ONOO−). Peroxynitrite is a strong pro-oxidant molecule 
which causes lipid peroxidation and tissue injury (Hogg 
et al. 2017). In addition, hypertension itself leads to 
enhanced production of ROS. Previous studies had shown 
that in different models of systemic hypertension, there 
would be enhancement of O2- and superoxide-producing 
enzymes, regardless of how the hypertension was induced 
(Drummond & Sobey 2014; García-Redondo et al. 2016).
Malondialdehyde exists in the serum, plasma, tissues as 
well as in the urine. It is the commonest analytic estimation 
of lipid peroxidation and oxidative stress that has been 
reported (Chen et al. 2015). In the present study, the level 
of MDA was increased in the L-NAME-induced hypertensive 
rats; indicating that oxidative stress plays an important 
role in the pathophysiology of hypertension (Baradaran 
et al. 2014). Treatment of L-NAME-induced hypertensive 
rats with AEPS caused reduction in MDA level. This 
finding is in accordance to a recent study which showed 
that PS significantly reduced MDA level in spontaneously 
hypertensive rats (Zainudin et al. 2015).
 Decreased level of MDA in AEPS treated group could 
be attributed to the antioxidant effects of PS. PS had been 
proven to have strong antioxidant activity (Ugusman et al. 
2012). Besides, PS had been shown to suppress intercellular 
adhesion molecule-1 (ICAM-1) and NADPH oxidase 4 
(Nox4) expressions in oxidative stress-induced HUVECs. 
Nox4 is the predominant enzyme for ROS production 
in endothelial cells (Ugusman et al. 2010). Several 
chemical compounds with antioxidant activities found in 
PS are polyphenols, vitamins C and E, carotenes, tannins, 
xanthophylls, flavonoids and amides (Hussain et al. 2015). 
Polyphenols had been shown to reduce blood pressure in 
NO-deficient model of hypertension (Bernátová et al. 2002; 
Rodrigo et al. 2016). Since this study used crude extract 
of PS and not its isolated bioactive components, this study 
was unable to specify the active compound responsible 
for the antihypertensive effect. However, it is suggested 
that the antihypertensive effect of PS in NO-deficient 
model of hypertension observed in this study is due to its 
polyphenols content.
CONCLUSION
AEPS reduces blood pressure in L-NAME-induced 
hypertensive rats and the antihypertensive effect may be 
partly mediated by increased NO and reduced oxidative 
stress. Our findings suggest that AEPS has the potential 
to be developed as a therapeutic agent for hypertension. 
However, further studies using isolated bioactive 
components from AEPS are required in order to support the 
therapeutic potential of AEPS for hypertension.
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